2:36 PM
Dec 05, 2018
 |  BC Extra  |  Company News

Management tracks: Glympse, Kaleido, Lundbeck

Non-invasive sensor company Glympse Bio Inc. (Cambridge, Mass.) hired Caroline Loew as the company's first president and CEO. Loew was VP and head of R&D strategy and planning at Bristol-Myers Squibb Co. (NYSE:BMY). Glympse also appointed serial entrepreneur Robert Langer to its board.

Microbiome company Kaleido Biosciences Inc. (Bedford, Mass.) hired Katharine Knobil as CMO and head of R&D. She was CMO of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK).

H. Lundbeck A/S (CSE:LUN) said EVP and Head of R&D Anders Gersel will retire Dec. 31. He joined the neurology company in 2000. H. Lundbeck is searching for a successor.

Stifel Financial Corp. (NYSE:SF) hired Sean Cessna as managing director and Titus Phoro as director in the firm’s investment banking group to lead investments in biopharmaceuticals. Cessna was head of healthcare investment banking at JMP Securities, and Phoro was a director in the healthcare investment banking group at JMP.

Antibody company ChemomAb Ltd. (Tel Aviv, Israel) appointed Stephen Squinto as chairman. He is a partner at OrbiMed Advisors.

Cancer company Sesen Bio Inc. (NASDAQ:SESN) hired Dennis Kim as CMO. He was principal and CMO at biotech consultancy Panthera Life Sciences.

H.C. Wainwright hired Vernon Bernardino as managing director and senior biotechnology analyst. He previously covered biotech as managing director and senior analyst at Seaport Global Securities.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD